These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25959119)

  • 21. [Legal issues in the off-label use of drug medication in in pediatrics].
    Poetsch J
    J Dtsch Dermatol Ges; 2006 May; 4(5):421-6. PubMed ID: 16686611
    [No Abstract]   [Full Text] [Related]  

  • 22. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.
    Sengupta P; Chatterjee B; Tekade RK
    Int J Pharm; 2018 May; 543(1-2):328-344. PubMed ID: 29635054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International Conference on Harmonisation; Guidance on Q8 Pharmaceutical Development; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 May; 71(98):29344-5. PubMed ID: 16749216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The EU's new paediatric medicines legislation: serving children's needs?
    Permanand G; Mossialos E; McKee M
    Arch Dis Child; 2007 Sep; 92(9):808-11. PubMed ID: 17715445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Necessity of rethinking oral pediatric formulations.
    Bar-Shalom D
    Clin Ther; 2014 Feb; 36(2):180-3. PubMed ID: 24529290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usage of unpublished paediatric data.
    Saint-Raymond A; Pelle B; Zaccaria C; Sennwitz M; Branch S
    Arch Dis Child; 2016 Jan; 101(1):81-4. PubMed ID: 26543071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risks, regulation, and rewards in new drug development in the United States.
    DiMasi JA
    Regul Toxicol Pharmacol; 1994 Apr; 19(2):228-35. PubMed ID: 8041920
    [No Abstract]   [Full Text] [Related]  

  • 30. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the new european paediatric regulatory framework on ethics committees: overview and perspectives.
    Altavilla A; Manfredi C; Baiardi P; Dehlinger-Kremer M; Galletti P; Pozuelo AA; Chaplin J; Ceci A
    Acta Paediatr; 2012 Jan; 101(1):e27-32. PubMed ID: 21732978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on registration administration of extracts of traditional Chinese medicine and its preparation].
    Zhang JW
    Zhongguo Zhong Yao Za Zhi; 2013 May; 38(10):1627-30. PubMed ID: 23947153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical assessment of pharmaceutical processes--A rationale for changing the synthetic route.
    Butters M; Catterick D; Craig A; Curzons A; Dale D; Gillmore A; Green SP; Marziano I; Sherlock JP; White W
    Chem Rev; 2006 Jul; 106(7):3002-27. PubMed ID: 16836307
    [No Abstract]   [Full Text] [Related]  

  • 34. Antidote shortages in the USA: impact and response.
    ;
    J Med Toxicol; 2015 Mar; 11(1):144-6. PubMed ID: 25711999
    [No Abstract]   [Full Text] [Related]  

  • 35. [Why create a exclusive law for the development of drugs in pediatrics?].
    Marotti M
    Rev Assoc Med Bras (1992); 2008; 54(2):98-9. PubMed ID: 18506310
    [No Abstract]   [Full Text] [Related]  

  • 36. Challenges of developing palatable oral paediatric formulations.
    Cram A; Breitkreutz J; Desset-Brèthes S; Nunn T; Tuleu C;
    Int J Pharm; 2009 Jan; 365(1-2):1-3. PubMed ID: 18848611
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new approach to the safety assessment of pharmaceutical excipients. The Safety Committee of the International Pharmaceutical Excipients Council.
    Steinberg M; Borzelleca JF; Enters EK; Kinoshita FK; Loper A; Mitchell DB; Tamulinas CB; Weiner ML
    Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 1):149-54. PubMed ID: 8933628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
    Vassal G
    Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.